Breaking News Instant updates and real-time market news.

AGN

Allergan

$204.65

1.99 (0.98%)

16:57
09/22/17
09/22
16:57
09/22/17
16:57

Allergan receives refusal to file letter from FDA for Vraylar

Allergan announced that it received a refusal to file, or RTF letter from the FDA regarding its supplemental new drug application, or sDNA, for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. Vraylar is an oral, once daily atypical antipsychotic approved in the U.S. for the treatment of schizophrenia and the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder. Upon its preliminary review, the FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review. Cariprazine is approved in Europe for the treatment of schizophrenia. "We are disappointed with the FDA decision on our submission. We will request a meeting with FDA to discuss and determine our next steps. Vraylar is an important treatment option for patients suffering from bipolar I disorder and schizophrenia. We remain committed to our mental health program and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia," said David Nicholson CRDO, Allergan.

  • 25

    Sep

AGN Allergan
$204.65

1.99 (0.98%)

09/20/17
SBSH
09/20/17
NO CHANGE
Target $280
SBSH
Buy
Allergan pipeline largely out of the shares, says Citi
Citi analyst Liav Abraham believes Allergan's pipeline remains largely out of the share price. In a research not titled "Emerging from the Twilight Zone. Reiterating Buy Rating," the analyst admits the outcome of the Restasis district court litigation remains a near-term overhang on the stock. She believes, however, that Allergan's pipeline will become a "more meaningful part of the debate heading into 2018." The company's nonalcoholic steatohepatitis opportunity, as well as its migraine assets, could generate $3B in peak non-risk-adjusted sales, which is largely not discounted in the current valuation, Abraham contends. She lowered her price target for Allergan shares to $280 from $290 and keeps a Buy rating on the name.
09/20/17
MSCO
09/20/17
DOWNGRADE
MSCO
Equal Weight
Allergan downgraded to Equal Weight from Overweight at Morgan Stanley
09/20/17
09/20/17
DOWNGRADE
Target $228

Equal Weight
Allergan cut to Equal Weight on lower margin assumptions at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger downgraded Allergan to Equal Weight from Overweight, explaining that he previously projected growth above the average of its Major Pharma peers, but he now has less conviction in its pipeline catalysts, sees more Restasis patent risk and he no longer expects margin expansion because high gross margin products face generic pressures. The analyst lowered his longer-term margin assumptions for Allergan and cut his price target on the stock to $228 from $284.
09/22/17
WELS
09/22/17
NO CHANGE
Target $276
WELS
Outperform
Allergan trial not successful, but overhang removed, says Wells Fargo
Wells Fargo analyst David Maris says the best he can say about Allergan's data today for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis is that Cenicriviroc "seems safe and it may have a benefit in some patients." Overall, the study was not a success, but the good safety and other data support further study, Maris tells investors in a research note titled "Data Mixed, One Overhang Gone." The analyst keeps an Outperform rating on Allergan shares with a $276 price target.

TODAY'S FREE FLY STORIES

09:10
10/17/17
10/17
09:10
10/17/17
09:10
General news
FX Action: The dollar »

FX Action: The dollar…

TDC

Teradata

$32.97

-0.24 (-0.72%)

, GE

General Electric

$23.36

0.38 (1.65%)

09:09
10/17/17
10/17
09:09
10/17/17
09:09
Hot Stocks
GE Aviation and Teradata partner for airline analytics solutions »

GE (GE) Aviation and…

TDC

Teradata

$32.97

-0.24 (-0.72%)

GE

General Electric

$23.36

0.38 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 02

    Nov

V

Visa

$108.30

-0.36 (-0.33%)

09:08
10/17/17
10/17
09:08
10/17/17
09:08
Hot Stocks
Visa and Billtrust partner for B2B virtual card acceptance »

Visa and Billtrust today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Nov

DGX

Quest Diagnostics

$91.53

0.47 (0.52%)

09:07
10/17/17
10/17
09:07
10/17/17
09:07
Recommendations
Quest Diagnostics analyst commentary  »

Quest Diagnostics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

HOG

Harley-Davidson

09:07
10/17/17
10/17
09:07
10/17/17
09:07
Recommendations
Harley-Davidson analyst commentary  »

Harley-Davidson Q3 beat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HOG

Harley-Davidson

$46.57

-0.05 (-0.11%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
Harley-Davidson says Q3 international performance down »

Sees tremendous interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AMDA

Amedica

$0.29

-0.01049 (-3.46%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
Amedica receives positive Nasdaq listing decision »

Amedica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$13.51

0.31 (2.35%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
MiMedx warns of fake emails »

MiMedx Group warned that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 08

    Nov

  • 09

    Nov

  • 10

    Nov

  • 13

    Nov

  • 14

    Nov

BUD

AB InBev

$125.72

0.36 (0.29%)

09:05
10/17/17
10/17
09:05
10/17/17
09:05
Hot Stocks
Anheuser-Busch, Convoy sign multiyear partnership to advance shipping operations »

Anheuser-Busch and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

09:05
10/17/17
10/17
09:05
10/17/17
09:05
General news
U.S. equities are trading sideways »

U.S. equities are trading…

BKI

Black Knight

$46.85

0.05 (0.11%)

09:04
10/17/17
10/17
09:04
10/17/17
09:04
Hot Stocks
Black Knight, Homebot announce strategic alliance »

Black Knight announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MS

Morgan Stanley

$48.94

0.64 (1.33%)

09:03
10/17/17
10/17
09:03
10/17/17
09:03
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

CELG

Celgene

$136.71

0.25 (0.18%)

09:03
10/17/17
10/17
09:03
10/17/17
09:03
Initiation
Celgene initiated  »

Celgene initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

ROKU

Roku

$22.19

-0.83 (-3.61%)

09:02
10/17/17
10/17
09:02
10/17/17
09:02
Hot Stocks
Roku expands further into Latin America, to launch two players in region »

Roku, Inc. announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEOT

Neothetics

$0.52

-0.0206 (-3.81%)

09:02
10/17/17
10/17
09:02
10/17/17
09:02
Hot Stocks
Neothetics, Evofem Biosciences announce all-stock merger »

Neothetics (NEOT) and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$22.19

-0.83 (-3.61%)

09:01
10/17/17
10/17
09:01
10/17/17
09:01
Hot Stocks
Roku launches Roku Express in Canada »

Roku, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

09:01
10/17/17
10/17
09:01
10/17/17
09:01
Syndicate
Abeona Therapeutics 5M share Spot Secondary priced at $16.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 17

    Oct

NFLX

Netflix

09:00
10/17/17
10/17
09:00
10/17/17
09:00
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Fed funds futures are modestly lower, having unwound early gains »

Fed funds futures are…

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Industrial Production to be reported at 09:15 »

September Industrial…

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Industrial Production Capacity Utilization Rate to be reported at 09:15 »

September Industrial…

ACN

Accenture

$139.09

-0.11 (-0.08%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Hot Stocks
Accenture enters into exclusive negotiations to acquire Altima »

Accenture has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Earnings
Johnson & Johnson backs FY17 revenue view $75.9B-$76.2B, consensus $75.83 »

Guidance in constant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

LRCX

Lam Research

$192.36

2.46 (1.30%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Recommendations
Lam Research analyst commentary  »

Lam Research added to US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:57
10/17/17
10/17
08:57
10/17/17
08:57
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.